10-KPeriod: FY2018

BIOGEN INC. Annual Report, Year Ended Dec 31, 2018

Filed February 6, 2019For Securities:BIIB

Summary

Biogen Inc. reported robust financial performance in its 2019 10-K filing, driven by strong sales in its core Multiple Sclerosis (MS) franchise and significant growth from its Spinal Muscular Atrophy (SMA) treatment, SPINRAZA. The company demonstrated solid revenue growth year-over-year, supported by its diverse portfolio and strategic collaborations. Key strategic moves in 2018 included expanding its ownership in the Samsung Bioepis biosimilar joint venture and entering into several new collaborations and acquisitions to bolster its pipeline in neurology and neurodegenerative diseases. Despite facing a competitive landscape and ongoing pricing pressures, Biogen maintained a strong focus on innovation and expanding its therapeutic reach, with a significant portion of its R&D investment directed towards challenging diseases like Alzheimer's and Parkinson's. The company also highlighted its commitment to returning capital to shareholders through its share repurchase program.

Financial Highlights

56 data points
Beta

Revenue

$13.45B

86.5% Gross Margin

Net Income

$4.43B

32.9% Net Margin

EPS (Diluted)

$21.58

Total Assets

$25.29B

Cash & Equivalents

$1.22B

Free Cash Flow

$5.42B

Financial Statements
Beta
Revenue$13.45B
Cost of Revenue$1.82B
Gross Profit$11.64B
SG&A Expenses$2.11B
Operating Expenses$7.56B
Operating Income$5.89B
Interest Expense$200.60M
Net Income$4.43B
EPS (Basic)$21.63
EPS (Diluted)$21.58
Shares Outstanding (Basic)204.90M
Shares Outstanding (Diluted)205.30M

Key Highlights

  • 1Biogen's Multiple Sclerosis (MS) products, particularly TECFIDERA, continued to be significant revenue drivers, though the company noted a slight decline in overall MS product revenues due to increased competition and patient transitions.
  • 2SPINRAZA, the company's treatment for Spinal Muscular Atrophy (SMA), showed substantial revenue growth, becoming a key contributor to the company's overall financial performance.
  • 3The company increased its ownership in Samsung Bioepis to approximately 49.9%, strengthening its position in the biosimilars market.
  • 4Significant investments were made in R&D, with a focus on pipeline expansion in neurocognitive disorders, acute neurology, and pain, alongside continued efforts in core areas like Alzheimer's disease.
  • 5A new 10-year exclusive agreement was closed with Ionis Pharmaceuticals to develop novel antisense oligonucleotide drug candidates for a broad range of neurological diseases.
  • 6Biogen announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis (RMS) in collaboration with AbbVie.
  • 7The company continued its share repurchase program, authorizing up to $3.5 billion in repurchases in August 2018.

Frequently Asked Questions

Biogen's key growth drivers were its Multiple Sclerosis (MS) franchise, particularly TECFIDERA, and significant revenue increases from its Spinal Muscular Atrophy (SMA) treatment, SPINRAZA. The company also saw growth from its biosimilar products and its share of revenues from anti-CD20 therapeutic programs.

In 2018, Biogen strategically increased its ownership in Samsung Bioepis to nearly 50%, entered into a significant collaboration with Ionis Pharmaceuticals for neurological disease therapies, acquired several early-stage assets (BIIB100, BIIB104, BIIB110), and exercised options for other promising candidates (BIIB067). These moves underscore a focus on pipeline expansion and diversification.

Biogen faced intense competition in the biopharmaceutical industry, particularly within the MS market, which led to a slight decrease in MS product revenues. The company also noted global pricing pressures and the ongoing need to manage costs in a complex regulatory environment. The voluntary withdrawal of ZINBRYTA also impacted revenue streams.

Biogen is significantly investing in research and development across its core and emerging growth areas, with a particular focus on Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative and neurological disorders. Strategic collaborations, acquisitions, and the development of new technologies like gene therapy are central to its future growth strategy.